NEW YORK (GenomeWeb News) – GeneGo said today that the VTT Technical Research Centre of Finland, a developer of novel high-throughput methods for cancer research, drug discovery, and diagnostics, has licensed the company’s software suite.
Under the agreement, VTT will use the MetaCore and MetaDrug software in compound screening, RNA interference experiments, cell biology, and bioinformatics projects to identify pathways and networks for cancer research projects.
These projects include studies of the mechanisms of cancer development and progression, therapeutics research, and the actions of anti-cancer compounds.
VTT’s Medical Biotechnology Knowledge Centre is funded by the European Commission and the Academy of Finland.
Financial terms of the agreement were not released.